Dr. Moller has extensive experience in biopharmaceutical R&D. He currently serves as Chief Scientific Officer (CSO) at Poxel, a clinical stage biopharmaceutical company developing therapeutics for metabolic diseases including rare disorders and non-alcoholic steatohepatitis (NASH). Prior to joining Poxel, he was CSO at Sigilon Therapeutics, a biotechnology company developing a new class of engineered cell-based medicines. Previously, he served in senior R&D and business development roles at Eli Lilly and Merck which led to the launch of several new medicines; while on the faculty at Harvard, his laboratory discovered key mechanisms underlying the pathogenesis of metabolic disorders. Dr. Moller has published more than 130 peer-reviewed papers. His honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an Adjunct Professor at the Karolinska Institute. He holds an MD from the University of Cincinnati and completed clinical and research training programs at the George Washington and Harvard Universities.